Talazoparib (BMN 673; MDV3800)
This product is for research use only, not for human use. We do not sell to patients.
For small sizes, please check our retail website as below: www.invivochem.com
| Size | Price | Stock |
|---|---|---|
| 500mg | $1150 | In Stock |
| 1g | $2100 | In Stock |
| 5g | $6200 | In Stock |
: Cat #: V0304 CAS #: 1207456-01-6 Purity ≥ 98%
Description: Talazoparib (formerly BMN-673 and MDV-3800; trade name: Talzenna), is a novel, highly potent and orally bioavailable PARP1/2 [poly(ADP-ribose) polymerase] inhibitor approved for cancer treatment.
Top Publications Citing Invivochem Products
Publications Citing InvivoChem Products
Product Promise
- Physicochemical and Storage Information
- Protocol
- Related Biological Data
- Stock Solution Preparation
- Quality Control Documentation
| Molecular Weight (MW) | 380.35 |
|---|---|
| Molecular Formula | C19H14F2N6O |
| CAS No. | 1207456-01-6 |
| Storage | -20℃ for 3 years in powder formr |
| -80℃ for 2 years in solvent | |
| Solubility In Vitro | DMSO: 38 mg/mL (99.9 mM)r |
| Water: <1 mg/mLr | |
| Ethanol: <1 mg/mL | |
| Synonyms | BMN 673; BMN673; MDV-3800; MDV 3800; MDV3800; BMN-673; LT673; LT 673; LT-673; Talazoparib; trade name: Talzenna |
| Protocol | In Vitro | Talazoparib shows EC50s of 0.3 nM, 5 nM and 0.31 for MX-1 cells (BRCA1 mutant), Capan-1 cells (BRCA2 mutant) and MRC-5 cells (normal).Talazoparib shows an EC50 of 2.51 nM in cellular PARylation assay |
|---|---|---|
| In Vivo | Talazoparib exhibits moderate oral bioavailability (rat 56%) and Cmax (rat 7948 ng/mL) following oral administration (rat 10 mg/kg). Talazoparib exhibits the terminal elimination half-life (rat 2.25 h) due to plasma clearance (2 mL/min/kg) following intravenous administration (rat 5 mg/kg).Talazoparib (0.33 mg/kg; i.g.; once daily; for 28 days) exhibits antitumor activity against BRCA1 mutant breast cancer model in mice | |
| Animal model | Female athymic nu/nu mice (8-10 weeks old), with MX-1 xenograft-bearing mice | |
| Dosages | 0.33 mg/kg | |
| Administration | Oral gavage, once daily, for 28 days |
These protocols are for reference only. InvivoChem does not
independently validate these methods.
| Solvent volume to be added | Mass (the weight of a compound) | |||
|---|---|---|---|---|
| Mother liquor concentration | 1mg | 5mg | 10mg | 20mg |
| 1mM | 2.6292 mL | 13.1458 mL | 26.2916 mL | 52.5831 mL |
| 5mM | 0.5258 mL | 2.6292 mL | 5.2583 mL | 10.5166 mL |
| 10mM | 0.2629 mL | 1.3146 mL | 2.6292 mL | 5.2583 mL |
| 20mM | 0.1315 mL | 0.6573 mL | 1.3146 mL | 2.6292 mL |
The molarity calculator equation
Mass(g) = Concentration(mol/L) × Volume(L) × Molecular Weight(g/mol)
Mass
=
Concentration
×
Volume
×
Molecular Weight*
The dilution calculator equation
Concentration(start)
×
Volume(start)
=
Concentration(final)
×
Volume(final)
This equation is commonly abbreviated as: C1 V1 = C2 V2
Concentration(start)
C1
×
Volume(start)
V1
=
Concentration(final)
C2
×
Volume(final)
V2
Step One: Enter information below
Dosage mg/kg
Average weight of animals g
Dosing volume per animal µL
Number of animals
Step Two: Enter the in vivo formulation
%DMSO
+
%
+
%Tween 80
+
%ddH2O
Calculation Results:
Working concentration:
mg/ml;
Method for preparing DMSO master liquid:
mg
drug pre-dissolved in
µL
DMSO(Master liquid concentration
mg/mL)
,Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:
Take
µL
DMSO master liquid, next add
µL
PEG300, mix and clarify, next add
µL
Tween 80,mix and clarify, next add
µL
ddH2O,mix and clarify.
Note:
- (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
- (2) Be sure to add the solvent(s) in order.